CD274 and neoplasm: Durvalumab has been approved for the treatment of stage III NSCLC regardless of tumor PD-L1 status and the presence of EGFR mutations although the data from the PACIFIC study showed no improvement in survival with durvalumab in patients without PD-L1 expression on tumor cells (HR = 1.14, 95% CI: 0.7–1.84).